Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000167506 | SCV000218364 | likely benign | Hereditary cancer-predisposing syndrome | 2014-12-31 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000640408 | SCV000761999 | likely benign | Familial adenomatous polyposis 2 | 2024-04-15 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000167506 | SCV001357389 | likely benign | Hereditary cancer-predisposing syndrome | 2019-09-05 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001753575 | SCV001996172 | uncertain significance | not provided | 2019-09-19 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek 2016); Has not been previously published as pathogenic or benign to our knowledge; In-silico analysis, which includes splice predictors and evolutionary conservation, is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown. |